CD8A and neoplasm: A prominent post-treatment induction of MAGE-A3-specific (peptide p271–279 FLWGPRALV) CD8+ T-cells in PBMCs was seen 29 d after treatment initiation suggesting that intratumoral treatment with ONCOS-102 elicits systemic tumor specific immunity despite the presence of viral antigens (Fig. 2).